ARTIFICIAL INTELLIGENCE-ASSISTED RADIOTHERAPY FOR PELVIC AND ABDOMINAL MALIGNANCIES: ASSESSING FEASIBILITY IN THE CONTEXT OF AFRICA‑SPECIFIC RISKS - Scorecard - MDSpire

ARTIFICIAL INTELLIGENCE-ASSISTED RADIOTHERAPY FOR PELVIC AND ABDOMINAL MALIGNANCIES: ASSESSING FEASIBILITY IN THE CONTEXT OF AFRICA‑SPECIFIC RISKS

  • By

  • Fiagbedzi, Emmanuel

  • Acquah, George Felix

  • Baidoo, Alhassan Mohammed

  • Osei- Poku, Linda

  • Pokoo-Aikins, Mark

  • Dery, Theresa

  • Agyabeng, Annette

  • Issahaku, Shirazu

  • Sackey, Theophilus Akumea

  • Adu-Poku, Mary

  • Sosu, Edem Kwabla

  • Tagoe, Samuel Nii Adu

  • Addison, Eric Clement Kotei

  • Hasford, Francis

  • Stoeva, Magdalena

  • May 1, 2026

  • 0 min

Share

Clinical Scorecard: EVALUATING THE VIABILITY OF AI-ENHANCED RADIOTHERAPY FOR ABDOMINAL AND PELVIC CANCERS IN THE FACE OF AFRICAN CONTEXTUAL CHALLENGES

At a Glance

CategoryDetail
ConditionPelvic and abdominal cancers
Key MechanismsAI tools for auto-contouring, treatment planning support, quality assurance, and workflow optimisation
Target PopulationPatients with pelvic and abdominal malignancies in Africa
Care SettingRadiotherapy facilities in Africa

Key Highlights

  • AI tools for auto-contouring, treatment planning support, quality assurance, and workflow optimisation can improve efficiency and ease workload when implemented within appropriate clinical and governance frameworks.

Guideline-Based Recommendations

Diagnosis

    Management

    • Implement AI tools within appropriate clinical and governance frameworks.

    Monitoring & Follow-up

      Risks

      • Address regulatory gaps and weak data governance.
      • Mitigate risks from non-African training datasets.

      Patient & Prescribing Data

      Patients with pelvic and abdominal cancers in Africa

      AI-enhanced radiotherapy can act as a capacity multiplier.

      Clinical Best Practices

        Related Resources & Content

          Original Source(s)

          ARTIFICIAL INTELLIGENCE-ASSISTED RADIOTHERAPY FOR PELVIC AND ABDOMINAL MALIGNANCIES: ASSESSING FEASIBILITY IN THE CONTEXT OF AFRICA‑SPECIFIC RISKS

          • by Fiagbedzi, Emmanuel , Acquah, George Felix, Baidoo, Alhassan Mohammed, Osei- Poku, Linda , Pokoo-Aikins, Mark , Dery, Theresa , Agyabeng, Annette , Issahaku, Shirazu , Sackey, Theophilus Akumea, Adu-Poku, Mary , Sosu, Edem Kwabla, Tagoe, Samuel Nii Adu, Addison, Eric Clement Kotei, Hasford, Francis , Stoeva, Magdalena

          • May 1, 2026

          Related Content

          Is full adherence mandatory? Real-world outcomes of completing perioperative chemoimmunotherapy in resectable non-small cell lung cancer

          MRI perfusion in evaluating ovarian masses: diagnostic performance of wash out rate

          VANGL1 links angiogenesis–stemness programs and tumor microenvironment remodeling: a pan-cancer, multi-omics study with translational validation